Silexion Therapeutics GAAP EPS of -$2.88

* Silexion Therapeutics press release [https://seekingalpha.com/pr/20303996-silexion-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business] (SLXN [https://seekingalpha.com/symbol/SLXN]): Q3 GAAP EPS of -$2.88.
* As of September 30, 2025, Silexion had cash and cash equivalents of $9.2 million, compared to $1.2 million as of December 31, 2024.

MORE ON SILEXION THERAPEUTICS

* Seeking Alpha’s Quant Rating on Silexion Therapeutics [https://seekingalpha.com/symbol/SLXN/ratings/quant-ratings]
* Historical earnings data for Silexion Therapeutics [https://seekingalpha.com/symbol/SLXN/earnings]
* Financial information for Silexion Therapeutics [https://seekingalpha.com/symbol/SLXN/income-statement]